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Abstract 
Proteases were traditionally viewed as mere protein-degrading enzymes with a very 
restricted spectrum of substrates. A major expansion in protease research has uncovered a 
variety of novel substrates, and it is now evident that proteases are critical pleiotropic actors 
orchestrating pathophysiological processes. Recent findings evidenced that the net proteolytic 
activity also relies upon interconnections between different protease and protease inhibitor 
families in the protease web. In this review, we provide an overview of these novel concepts 
with a particular focus on pulmonary pathophysiology. We describe the emerging roles of 
several protease families including cysteine and serine proteases. The complexity of the 
protease web is exemplified in the light of multidimensional regulation of serine protease 
activity by matrix metalloproteases through cognate serine protease inhibitor processing. 
Finally, we will highlight how deregulated protease activity during pulmonary pathogenesis 
may be exploited for diagnosis/prognosis purposes, and utilized as a therapeutic tool using 
nanotechnologies. Considering proteases as part of an integrative biology perspective may 
pave the way for the development of new therapeutic targets to treat pulmonary diseases 
related to intrinsic protease deregulation. 
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Introduction 
Proteases represent almost 2% of the human genome comprising 565 members [1, 2]. 
Based on their different catalytic mechanisms, five major classes of proteases are known in 
mammals including serine, cysteine, metallo, aspartic, and threonine proteases, the three first 
families being the most widespread in humans [3]. Protease activity requires tight regulation 
(Figure 1): elevated protease levels, actively contributing to disease progression, constitute a 
common feature shared by a broad range of pulmonary pathologies, including idiopathic 
pulmonary fibrosis (IPF), cystic fibrosis (CF), emphysema or infection, [4]. The underlying 
mechanisms of such observations have long remained elusive: indeed, proteases were 
traditionally viewed as mere protein-degrading enzymes with a restricted spectrum of 
substrates. During the last decade, a major expansion in protease research from different fields 
dramatically shifted this paradigm. The study of degradomics (the protease substrate 
repertoire) revealed that the nature of the dedicated substrates of proteases, and the biological 
effects triggered by their processing, are exceptionally diverse [5]. Proteases are now 
considered as key components of regulatory mechanisms, through irreversible cleavage of 
substrates resulting in their activation, inactivation, or modulation of function. The serine 
proteases of the coagulation cascade constitute an archetypal example: beyond blood clot 
formation, these proteases contribute to a variety of pathophysiologies, including IPF, through 
the irreversible activation of their cellular receptors, the Protease-Activated Receptors[6, 7]. 
Cellular effects of other protease families, such as cysteine proteases or matrix-
metalloproteases (MMPs) began to unfold only recently. Additionally, recent evidences show 
a regulation of protease activity through interconnection of protease cascades (the protease 
web). 
In this review, these new concepts of integrative protease biology are discussed in the 
perspective of pulmonary pathophysiology. First, we highlight the striking role in lung 
pathogenesis of cysteine proteases, which were traditionally circumscribed to lysosomal 
degradation. We describe the recently discovered involvement of macrophage and neutrophil 
elastases, which (despite their names) actually belong to different clans, in CF. Defined 
localization of protease activity is exemplified by the involvement of A Disintegrin And 
Metalloproteinase (ADAM) proteases in lung inflammation. Next, we focus on the main 
protease inhibitors, including serpins, to summarize the mechanisms underlying 
serpinopathies, and review recent evidence on serpin regulation by MMPs, thereby bolstering 
the concept of the protease web. These data are recapitulated in Table 1. Finally, we highlight 
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how deregulated protease activity during pulmonary pathogenesis may be exploited for 
diagnosis/prognosis purposes and utilized as a therapeutic tool using nanotechnologies. 
 
Unusual suspects: the emerging role of cathepsins, neutrophil and macrophage elastases, 
and ADAMs in lung diseases 
Cysteinyl cathepsins: endolysosomal degradation and beyond 
It is only very recently that an unexpected role of cathepsins in lung diseases has 
emerged. Human cysteine cathepsins are a group of 11 papain-like lysosomal proteases 
including cathepsins B, H, L, C, X, F and O, and are ubiquitously expressed in most tissues 
whereas cathepsins V, K, S and W have a more limited expression profile. Such diverse 
tissue-specific expression suggests that their action is not limited solely to the bulk protein 
degradation, but that they are also involved in the regulation of specific cellular functions. All 
of this allows cathepsins to regulate a broad variety of important physiological processes, 
including intracellular protein turnover, immune response, bone remodelling and prohormone 
processing [8, 9].  
With respect to lung pathophysiology, cathepsins have a critical role in MHC II–
mediated antigen processing and presentation [3, 10, 11]. In addition, cathepsins, especially 
cathepsin K, have been found to have also major roles in the processing of TLR receptors, 
[10, 12, 13]. In CF, levels of cathepsins B, L and S are increased in patient bronchoalveolar 
lavage fluid (BALF) [14], with bronchial epithelium acting a source of cathepsin S [15]. 
However, several questions remain unanswered, such as their relative contribution to 
extracellular proteolysis (as secreted proteases) vs. intracellular proteolysis (as lysosomal 
proteases) remains to be determined, as well as the balance between degradation and/or 
processing of specific substrates. Over the last decade, the role for cathepsins K and B in IPF 
has also emerged. In IPF patients, cathepsin K is increased in fibroblasts from fibrotic tissues. 
Unexpectedly, in the murine model of bleomycin-induced pulmonary fibrosis, cathepsin K 
deficiency associates with more severe lesions.  And indeed, in fact, cathepsin K has a pivotal 
protective role in pulmonary homeostasis through collagen cleavage thereby contributing to 
the airway structural integrity [16-18]. Increased expression of cathepsin B was also observed 
in IPF patient-derived fibroblasts. Cathepsin B contributes to myofibroblast differentiation by 
triggering activation of the TGF-β1-driven canonical Smad 2-3 pathway [19]. Accordingly, 
 6 
cathepsin B inhibition and/or genetic silencing diminishes α-smooth muscle actin (SMA) 
expression and fibroblast differentiation.  
From the above, the use of cathepsin pharmacological inhibitors seems an obvious 
therapeutical intervention. However, the off-targets and/or side effects of cathepsin inhibitors 
remain to be fully elucidated. For instance, cathepsin S inhibitors efficiently reduce lung 
inflammation but can result in cartilage and bone degradation [20]. Cathepsin K inhibitors, 
developed for the treatment of osteoporosis, target cathepsin K collagenolytic activity and 
may impair collagen I turnover thus favoring lung fibrosis [21]. A reversible cathepsin B 
inhibitor, VBY-376, demonstrated potent activity in a mouse model of CCl4-induced liver 
fibrosis [22] (http://www.virobayinc.com/docs/AASLD_Poster_2010.pdf). Promising phase I 
trials for treatment of hepatic fibrosis were also obtained with VBY-376 
(http://adisinsight.springer.com/drugs/800031124). Since cathepsin B-driven responses are 
common in pulmonary and hepatic fibrosis, the use of VBY-376 may be appropriate for 
pulmonary fibrosis treatment.  
Overall, it has emerged from the last decade that, beyond lysosomal degradation, 
cathepsins are crucial actors in pulmonary homeostasis and further research is warranted to 
better delineate their role in pulmonary pathophysiology. 
 
Neutrophil and macrophage elastases in CF: old dogs, new tricks 
An imbalance between neutrophil-derived proteases (including neutrophil elastase 
(NE), cathepsin G (CatG), and proteinase 3 (PR3)) and extracellular inhibitors is considered 
an important pathogenic mechanism for a number of lung diseases[23-25]. It is assumed that 
unopposed CatG, NE and PR3 collectively cause severe lung damage and emphysema[26], 
further underscoring their importance in pathology (for review, see [27]). A fourth elastase-
related protease, NSP4, expressed in the lung, has been recently identified. Its proteolytic 
effects, controlled by natural serine protease inhibitors of the serpin-type, are most likely 
limited to the intracellular and pericellular microenvironment of activated neutrophils. The 
natural substrates of NSP4 however yet remain to be determined [28]. Recent studies on 
mouse NE revealed the existence of a new variant, created by the spontaneous conversion 
process of the single-chain (sc) form of NE into a specific two-chain (tc) form by 
autoprocessing. The existence of this tc NE could adversely affect the protease–antiprotease 
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balance in the lung during NE release, and may lead to the development of more efficient 
anti-elastase therapies[29]. 
Strikingly, recent studies in infants and preschool children with CF also identified the 
increased activity of NE as a key risk factor of the onset and progression of early 
bronchiectasis [30, 31]. In the context of chronic lung disease, NE is involved in a number of 
processes including induction of IL-8 expression, increased mucin secretion, inactivation of 
innate airway proteins and cell surface receptors all of which, combined, identify NE as a pro-
inflammatory molecule [32-34, 35 , 36 , 37 , 38 , 39]. Similarly, in other chronic lung 
diseases, including COPD, A1AT deficiency and bronchiectasis, NE is thought to contribute 
to disease pathogenesis[40 , 41, 42].  
However, it is in the CF airways where the most definitive role regarding NE's 
deleterious effects has been most clearly demonstrated as shown by the AREST CF group 
[31]. The development of the ENaC -overexpressing (ENaC-Tg) mouse, featuring CF-like 
airway surface dehydration, phenocopies key characteristics of CF in patients, including 
airway inflammation, mucus hypersecretion and obstruction, bacterial infection and structural 
lung damage [43-45]. Recent studies in this CF model demonstrated that genetic deletion of 
NE reduces airway neutrophilia, mucin expression, goblet cell metaplasia and distal airspace 
enlargement without compromising anti-bacterial host defense in vivo [46]. In addition, 
whole-genome expression studies identified macrophage elastase (matrix metalloproteinase 
(MMP)-12) as a highly up-regulated gene in lungs from ENaC-Tg mice, and demonstrated 
that MMP12 also contributes to structural lung damage in vivo [47]. The clinical relevance of 
this finding is supported by a genetic study showing that a functional SNP (rs2276109) in the 
MMP12 promoter, previously associated with reduced lung function in COPD and asthma 
[48], was also associated with lung function decline in patients with CF [47]. More recent 
degradomic analysis of MMP12 in vivo reveals its broad substrate variety. For instance, 
MMP12 is potently anti-inflammatory in several in vivo models by cleaving and inactivating 
neutrophil chemokines [49], and terminating and complement factors, C4a and C5a [50,51].  
Taken together, these studies support important roles of elastases released from 
activated neutrophils and macrophages in the in vivo pathogenesis of multiple abnormalities 
in the CF lung including inflammation, mucus hypersecretion and structural lung damage. 
These studies also demonstrate that the ENaC-Tg mouse will be a useful model for further 
studies of the roles of other emerging proteases including serine proteases, matrix 
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metalloproteases and cysteine proteases [15, 24, 50], and their respective inhibitors, in the 
complex in vivo pathogenesis of CF and potentially other chronic inflammatory lung diseases. 
 
Localizing the activity to the membrane: A Disintegrin And Metalloproteinase 
(ADAM proteases)  
The ADAM proteins constitute a major class of membrane-anchored multidomain 
proteinases that are responsible for the shedding of cell-surface protein ectodomains, 
including the latent forms of growth factors, cytokines, and receptors. As such, they are 
described as “signaling scissors”. The ADAM family comprises ∼34 members, 22 of which 
have been described in humans. Only 13 human ADAMs carry the zinc-binding motif 
(HExxHxxGxxH) required for the proteolytic activity. Proteolytically active ADAMs can be 
regulated by induction of their gene transcription, by posttranslational mechanisms upon 
stimulation with cytokines or bacterial toxins, or, in some cases, by cleavage of their 
ectodomain and subsequent release of a soluble form [51, 52]. Several members of 
proteolytically active ADAMs are involved in lung disease. ADAM17 is critical for 
generation of proinflammatory mediators, especially TNF-alpha. The shedding of soluble 
activated TNF-alpha subsequently stimulates a cascade of events causing endothelial 
permeability and leukocyte recruitment. The overexpression of ADAM10 in lung epithelium 
causes the development of experimental emphysema [53]. ADAM10 has been identified as 
potential sheddase for CD23 and the soluble form of this mediator enhances the production of 
IgE [54]. Polymorphisms in the ADAM33 gene are linked with asthma or COPD [55] and 
BALF levels of the soluble form of this protease correlate with the severity of the disease 
[56]. Additionally, ADAM10 and 17 are critically involved in the shedding of several growth 
factors including TGFα for example [57]. ADAMs are also implicated in host defense against 
infectious agents. ADAM10 functions as a receptor for Staphylococcus aureus toxin, and 
epithelial ADAM10 deficiency can prevent lethal S. aureus infection [58]. Finally, a key role 
has been proposed for ADAMs in airway remodeling associated with asthma [59]. Based on 
the above, it has been postulated that ADAM inhibition would decrease edema formation, 
inflammatory cell recruitment, tissue remodeling, and reduction of S aureus toxicity. 
Accordingly, the use of a selective ADAM17 inhibitor suppressed LPS-induced lung 
inflammation in mice [51]. From the above it is evident that ADAM proteases are implicated 
in acute and chronic inflammation processes but also in infection and regeneration. As 
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inhibition of specific ADAMs might interfere with these processes, temporally and locally 
restricted and very specific inhibition strategies might be of interest for the treatment of lung 
disease. 
 
Proteases and natural serine protease inhibitors: the dangerous liaisons 
Besides an increase in protease expression and/or activation, deregulation of protease 
activity can arise from the loss of cognate protease inhibitors. Respiratory anti-proteases 
comprise serine protease inhibitors (serpins), tissue inhibitors of metalloproteinase (TIMPs), 
trappin-2/elafin, and secretory leukoprotease inhibitor (SLPI) [60]. These inhibitors not only 
neutralize protease activity, but also display anti-microbial and immune modulatory actions 
which are highly relevant in chronic lung pathologies, such as in cystic fibrosis and COPD, 
where there is a combination of infection and exacerbated host responses [61, 62]. The 
clinical importance of protease inhibition is supported by studies demonstrating that inhibitor 
deficiencies result in structural lung damage. For instance, serpinopathies are a relatively 
newly defined group of disorders, where the underlying cause is the accumulation of 
misfolded protein, or lack of protein expression, in the affected tissue (Figure 2). A1AT, a 
prototypical member of the serpin superfamily, is a specific inhibitor of NE, PR3 and catG 
[63]. Inherited A1AT deficiency (A1ATD), which causes familial emphysema and liver 
disease [64, 65], is a classic example of serpinopathies. A1ATD is most often associated with 
the Z (Glu342Lys) mutation. Z-type A1AT forms oligomeric complexe; the intra-cellular 
retention of such complexes (gain-of-function defect) cause cellular damage [66, 67]. 
Strikingly, cigarette smoke-mediated oxidation can enhance Z-A1AT polymerization in 
human alveolar epithelial cells and induce ER-stress and NF-кB-mediated pro-inflammatory 
cytokine (TNF-α, IL-6 and MCP-1) production [68, 69].  
Hence, anti-protease supplements may reduce the deleterious effects of unregulated 
NE activity. Accordingly, the therapeutic potential of natural endogenous inhibitors of 
proteases has gained interest over the last decade, and their newly appreciated functions point 
to extended therapeutic uses. Thus, human plasma-purified A1AT is used in infusion in 
A1ATD patients to delay the progression of emphysema. Administration of A1AT also 
triggers the anti-inflammatory pathways necessary for resolution of inflammation and 
prevention of tissue damage [70]. Inhalation therapy offers another opportunity for easier, 
more efficient delivery of A1AT directly to the lungs. Inhaled A1AT indeed significantly 
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ameliorates cigarette smoke-induced emphysema in the mouse [71]. In patients with CF, 
A1AT inhalation reduces airway inflammation[72]. Similarly, aerosolized recombinant SLPI 
reduces elastase activity in healthy subjects and CF patients [73]. Altogether, these data 
indicate the potential value of recombinant natural inhibitors in the treatment of chronic lung 
disease. 
Noteworthy, while cognate inhibitors are essential for protease activity regulation, 
recent evidence demonstrates that reciprocally, protease inhibitors are also protease 
substrates. Isotopic labels of cellular and secreted proteins in vitro and in vivo [74] revealed 
that serpins are major substrates of MMPs [75]. In other words, serine protease activity is 
regulated by MMPs through serpin processing. Accordingly, MMP2 cleaves serpin B6 and 
alpha-1 inhibitor III [76], while MMP14 processes SLPI [77]. Such a regulation of inhibitors 
through protease processing has significant consequences in pathophysiology. For instance, 
during lung inflammation, the cleavage of serpinA1 by MMP8 releases elastase activity in 
vivo [78]. In arthritis, a protective role for macrophage MMP12 was demonstrated: among 
other mechanisms, MMP12 induces antithrombin III degradation and increased thrombin 
activation [79]. In acute skin inflammation, MMP2 cleaves serpin G1, also known as 
complement C1 inhibitor. These findings have unveiled a mechanism, referred to as “metallo-
serpin switch”, by which MMP2 triggers complement cascade activation [74]. Altogether, 
these data revealed that proteases pervasively influence the activity of other proteases, either 
directly or by cleaving intermediate proteases or protease inhibitors. 
 
The Protease web: is there a maze in the lung? 
As the above-mentioned examples illustrate, proteases can no longer be thought of acting in 
isolation. Thus, proteases in the same or different families activate protease zymogens, 
inactivate proteases by autodegradation in trans, cleave and release protease substrate binding 
domains termed exosites (resulting in altered protease specificity and substrates), and, as 
exemplified above, cleave and inhibit protease inhibitors. By mapping these interactions of all 
reported biochemical validated cleavages in proteases and inhibitors uploaded to the data base 
MEROPS and TopFIND [80, 81], graph theory was used to bioinformatically map the 
protease interactions of proteases termed the protease web [78]. Remarkably, at the highly 
interconnected core of the protease web lie 255 highly connected proteases and inhibitors 
representing 50% of known proteases and inhibitors. Reachability analysis was performed, 
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whereby the connections between proteases and inhibitors (paths) were mapped, and both the 
connections that are direct ie. 1:1, and indirect ie. further downstream reached by one or more 
intermediate connections. Thus, within this core, 158 of these proteins reached over 153 
(60%) of the protease and inhibitors of the core, spanning all 5 human protease classes. The 
protease web is highly robust. Removal of one or more nodes did not “break” this highly 
interconnected core, nor did removal of paths. It was not until 40% of paths were removed did 
the web connectivity breakdown. Similarly it required removal of more than 6 proteases or 
inhibitors to destabilise the interconnected core. The connectivity will be shown to further 
increase as more protease and inhibitor interactions are uploaded to MEROPS and TopFIND 
by individual investigations upon publication of their data. The important implication of these 
analyses is that therapy must be designed with great care as blockade of one protease will 
almost inevitably have knock on effects to other proteases and activity via connections in the 
protease web and may explain the failure of previous protease inhibitor clinical trials [82-84]. 
Noteworthy, the above-mentioned findings have also recently emerged from other 
fields of research in addition to pulmonology. Since, as described earlier, several –if not all- 
of these actors have been shown to be involved in lung pathophysiology, it is therefore 
tempting to speculate that these mechanisms are highly relevant in lung disease, and further 
research in this direction is eagerly awaited. 
 
Protease activity: a tool for diagnosis?  
  Because elevated protease activity is associated with lung disease, it can be 
postulated that quantitative measurement of such an activity could serve as a surrogate marker 
for diagnosis/prognosis in lung diseases. A significant number of fluorescent probes have 
been developed to directly measure protease activities. Already in the late Seventies, short 
peptide-based molecules were developed that feature an intrinsic fluorescent entity.  
While commercially available and still heavily in use, sophisticated fluorescent reporters, 
often based on Foerster Resonance Energy Transfer (FRET), have been developed in recent 
years. Frequently, two fluorophores are employed as FRET donor and acceptor. This provides 
the possibility to measure FRET with a more sensitive readout in a ratiometric fashion, mostly 
independent from the amount of reporter present. Recent examples are FRET sensors for 
MMP12 (LaRee series) and neutrophil elastase (NEmo series) [85, 86], which have revealed 
elevated MMP-12 and NE activity. While such probes work extremely well with isolated 
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enzymes in the test tube, their application to biological samples is much more difficult. This is 
partly due to the fact that most proteases are counteracted by protease inhibitors, also present 
in mouse or patient samples. Further, the zymogen forms of proteases require cleavage for 
activation by other proteases and such activation seems to vary locally. For instance, when 
investigating MMP12 activity from mouse BAL samples by the soluble reporter LaRee1, very 
little activity was observed. However, the lipidated reporter LaRee1, located to the outer cell 
membrane of BAL macrophages, reported strong activity. This demonstrates that the enzyme 
activity resides predominantly on cell surfaces and suggests that the lung lumen is much less 
exposed [85]. Similarly, NE seems to be mostly blocked in its proteolytic activity in samples 
from lung lumen, but the lipidated reporter was cleaved readily on the surface of activated 
neutrophils [86]. FRET-based reporters have now made their way to patient samples and 
revealed, for instance, elevated strong increase in MMP12 and NE activity on the surface of 
airway neutrophils and macrophages from ENaC-Tg mice and patients with CF, respectively 
[46, 47]. Noteworthy, very recently, different cathepsin-targeted imaging probes were 
developed and successfully used to monitor fibrotic disease progression in the murine model 
of bleomycin-induced pulmonary fibrosis and in IPF patients [87]. In the future, an extended 
array of reporters will help to characterize the protease activity landscape on cells isolated 
from patients and will hopefully assist physicians for the diagnosis of lung diseases, possibly 
predict disease course and to devise treatment strategies. 
 
Hijacking protease activity for therapeutics 
Dysregulation of MMP activity is a characteristic feature of organ fibrosis [88] 
including in the lung [89] and malignant tumors [1, 90]. Recent progress in the field of 
nanotechnology has focused on the use of MMP-directed nanoparticles as diagnostic and 
therapeutic or theranostic devices [91-94]. Compared to commonly used drug and imaging 
formulations, nano-scaled drug carriers offer additional advantages such as increasing the 
drug circulation time, minimizing drug degradation, and overcoming first-pass drug 
metabolism [95]. Mesoporous silica nanoparticles, engineered to release their incorporated 
chemotherapeutic drug upon gate-opening by MMP2/9 cleavable linkers, have recently been 
developed [96]. Efficient drug release was shown to be strictly dependent on the presence of 
MMP9 in human lung tumor cell lines. Moreover, highly effective drug release from our 
MSN nanoparticles in mouse and human lung tumors. The successful application of 
therapeutic nanoparticles to ex vivo cultures of human lung tumors represents a major 
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progress in closing the translational gap in the development of novel MMP-targeted 
nanomedicines for lung tumor treatment. Thus, deregulation in protease activity in other lung 
diseases could be similarly hijacked for drug delivery and may represent a novel strategy for 
therapeutic intervention.  
 
Conclusion 
It is now clear that the traditional representation of proteases as mere ECM degrading 
enzymes has shifted. The new paradigm allows a better understanding of how proteases are 
instrumental in the pathogenesis of a variety of chronic lung diseases. Protease deregulation 
during pathogenesis may occur through escape to its tight, spatio-temporal, self-limiting 
control. The wide variety of protease substrates adds a further complexity to this field. Indeed, 
the examples described in this review emphasize that the close interplay between proteases, 
substrates and inhibitors, which are interrelated in the protease interactome accounting for the 
net proteolytic activity in the lung, should be taken into consideration. As a result of the 
recent emergence of the above-mentioned concepts, the understanding of the interplay and 
interdependency of these systems remains very scarce in the lung research field. 
Extrapolations of observations from different systems, together with translational approaches, 
combining degradomics data, murine models of lung disease and ex vivo observations from 
patients, should allow identification of an increasing number of instrumental proteases and 
protease inhibitors, in the perspective of integrative protease biology. Understanding in 
greater detail the complex molecular basis of regulation and function of protease activity will 
facilitate identification of new therapeutic targets as well as new diagnostic and prognostic 
tools for personalized medicine, and hopefully result in the development of new drugs to treat 
pulmonary diseases that result from inherent protease systems deregulation. 
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Figure legends 
Figure 1: More-than-normal protease activity in lung pathogenesis. In the normal lung 
(left), proteases (represented by scissors) are involved in lung homeostasis and their activity is 
tightly regulated by (among others) cognate protease inhibitors. (Right) In a diseased lung, 
elevated protease activity, which can occur through increased protease expression and/or loss 
in cognate protease inhibitor, results into imbalanced protease activity.  
Figure 2: Mechanisms underlying serpinopathies. Point mutations in the gene encoding 
may result into misfolded protein and misfolded serpin polymerization. Serpin polymers have 
no inhibitory functions towards serine proteases. Accumulation of serpin polymers has 
multiple cellular consequences. Other mutations can hinder protein expression. In either case, 
the loss of serpin results into uncontrolled proteolytic activity, thereby contributing to cell 
damage and the development of diseases. 
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Table 1: Proteases with extracellular function associated with chronic lung diseases: 
mechanisms of action within the airway microenvironment, reporters and selected 
(commercially available) pharmacological inhibitors 
PROTEASE 
 
MECHANISM OF ACTION REPORTER INHIBITORS 
 
C
YS
TE
IN
E 
P
R
O
TE
A
SE
S 
Cathepsin B Found in fibroblasts of IPF, contributes to 
myo-fibroblast differentiation via TGF-ß1, 
Smad 2-3 pathway [19]  
FRET reporter 
(Hu, unpublished 
observations) 
VBY-376 [22]  
Leupeptin   
E-64[15]  
Cathepsin K Cleaves collagen, 
increased in fibroblasts of fibrotic tissue in 
IPF [16-18]  
FRET reporter 
(Subramanian, 
unpublished 
observations) 
CTSK inhibitor II  
(Calbiochem) 
Cystatin C  [97]  
Cathepsin L Increased in BAL of CF patients, along with 
Cathepsin B & Cathepsin K [16]  
 Pentapeptide amide 
RKLLW-NH2  
Cathepsin S Lysosomal protease, unlike other 
cathepsins remains active at neutral pH 
[98] 
FRET reporter  
[99] 
Leupeptin  
E-64 [15]  
 
SE
R
IN
E 
P
R
O
TE
A
SE
S 
Cathepsin-G High affinity for nucleic acids, locates to 
NETs  [27] 
 Chymostatin   
NSP-4  Recently identified 4th neutrophil-derived 
protease (along with CTSG, NE & PR-3) 
substrate unknown [28] 
  
Neutrophil 
elastase 
Cleaves elastin, key risk factor for  
bronchiectasis in CF [29, 30], Induces IL-8, 
mucin secretion  [32-39]  
NEmo1, 
NEmo2[46]  
Sivelestat  
Elastase inhibitor V   
 
Proteinase-3 Degrades elastin [100]   
M
ET
A
LL
O
P
R
O
TE
A
SE
S 
ADAM-17 
(TACE) 
Initiates endothelial permeabilty and 
leukocyte recruitment via TNF generation 
[41, 42], involved in shedding TGFα [47] 
 TAPI-1[101]  
ADAM-10 Causes experimental emphysema[43], 
possible sheddase for CD23 [44], involved 
in shedding TGFα [47] 
 GI254023X [102]    
ADAM-33 Polymorphisms in ADAM-33 gene liked to 
Asthmas, COPD [45]  
FRET probe[103]  Anti-ADAM-33-
Antibody 
MMP-2 Cleaves type IV collagen, Serum MMP2 
correlates with severity of pulmonary 
hypertension [104] , cleaves Serpin B6 & 
alpha-1 inhibitor-3  [76] 
 GM6001  [105] 
Actinonin 
MMP-7 Possible marker for IPF (serum, BALF) [106]  GM6001  [105]  
Actinonin 
MMP-8 Cleaves SerpinA1, releasing elastase activity 
in vivo [78] 
 Actinonin 
MMP-9 
(gelatinase B) 
Cleaves type IV & V collagen, recruits 
leukocytes[107]  
FRET reporter 
(Halls, 
unpublished 
observations) 
GM6001  [105] 
Actinonin 
MMP-10 Possible marker for IPF (serum, BALF) [106]  GM6001  [105], 
Actinonin  [106] 
 22 
MMP-12 
(macrophage 
elastase) 
SNPs associated with lung function decline 
in COPD, asthma and CF [47, 48] 
Increased activity in smokers with COPD, 
asthma [35] and CF [36], associated with 
lung function decline in CF [47] 
LaRee1, LaRee5 
[85]  
GM6001 [105] 
MMP408 
Actinonin 
UK 370106 
MMP-14 Processes SLPI [77]  Anti-MMP-14-Antibody 
A
N
TI
P
R
O
TE
A
SE
S 
A1AT Serpin, inhibits NE, Cathepsin G, and 
Proteinase-3 [63], deficiency causes 
emphysema & liver disease [64, 65], 
therapeutic potential for COPD [71]  
  
Elafin 
(trappin-2) 
Inhibits proteases, anti-microbial, 
modulates immune response [50, 51]  
  
SLPI Inhibits proteases, anti-microbial, 
modulates immune response [50, 51], 
therapeutic potential for CF [73] 
  
   Inhibition type 
= competitive   
  = covalent 
 
A1AT=alpha-1 antitrypsin, ADAM=a disintegrin and metalloproteinase, BALF=bronchial 
alveolar lavage fluid, CAP=channel activating protease, CTS= cathepsin, LaRee=lavage 
reporter, NE=neutrophil elastase, NEmo=neutrophil elastase monitor, NETs=neutrophil 
extracellular traps, NSP-4=neutrophil serine protease-4, MMP=metalloprotease, 
SLPI=secretory leukocyte protease inhibitor  
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Figure 2 
 
